Novel Osteoinductive Biologics Products Help Regenerate Bone

Two synthetic calcium phosphate based bone substitute materials mimic the crystalline mineral structure of human bone.

EquivaBone is a combination of demineralized bone matrix (DBM) and a proprietary nanocrystalline calcium phosphate formulation that sets hard in vivo, and is both osteoconductive and osteoinductive. The combination product is moldable, injectable, and fast setting, and is used for repairing skeletal defects, regenerating bone and soft tissue, enabling controlled delivery of cells, biologics and therapeutic agents, and facilitating minimally invasive procedures. EquivaBone sets hard and remains in place once implanted. EquivaBone has approved by the U.S. Food and Drug Administration (FDA) for use in posterolateral spinal fusion.


CarriGen is a synthetic bone substitute that utilizes the same proprietary nanocrystalline calcium phosphate technology that is found in EquivaBone. As a pure synthetic, CarriGen is designed to set hard, and has compressive strength comparable to that of cancellous bone. CarriGen has high porosity, which allows it to absorb saline and/or blood when mixed. EquivaBone and CarriGen are products of ETEX Corporation (Cambridge, MA, USA).

"ETEX is pleased with the rapid expansion of clinical indications for our innovative biologic portfolio. Our product improvements and line extensions remain driven by direct surgeon feedback,” said Brian Ennis, president and CEO of ETEX Corporation. "This is reflected in the recent clearance of small size EquivaBone kits and the addition of blood and posterolateral spinal fusion indications to the labeling. We anticipate additional indications and platform extensions in the near term.”

Related Links:
ETEX Corporation